Clinical Focus

• Multiple Sclerosis
• Neuromyelitis Optica
• Transverse Myelitis
• Neurology

Administrative Appointments

• Director, Neurology Clerkship Program (2009 - present)
• Chair, MS Education Workgroup, Multiple Sclerosis Section; American Academy of Neurology (2011 - present)
• Councilor, Executive Committee, Multiple Sclerosis Section; American Academy of Neurology (2010 - present)
• Associate Director, Stanford Multiple Sclerosis Center (2008 - present)

Honors and Awards

• Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)
• AUPN Neurology Recruitment Award (highest percentage in U.S.), Association of University Professors of Neurology (2011)
• Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)
• Excellence in Neurology Clerkship Teaching Award, Stanford University Department of Neurology & Neurosciences (2008, 2009, 2010, 2011)
• Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)

Professional Education

Postdoctoral Advisees

Alexandra Goodyear

Graduate & Fellowship Program Affiliations

• Neurology and Neurol Sciences

Community and International Work

• Editorial Board 
• PACTRIMS Member 

Internet Links

• http://neurology.stanford.edu

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

Translational research in the human application of emerging immunotherapies for neurological disease, focusing on Multiple Sclerosis, CIS, transverse myelitis and Neuromyelitis Optica (NMO). Collaborative research with Stanford and extramural scientific faculty to identify biomarkers of disease activity and treatment response in humans. Clinical trials to assess efficacy of emerging treatments for MS, CIS and NMO, recently including trials of alemtuzumab, oral sphingosine 1 phosphate inhibition, NIH CombiRx and Biomarkers, Subcutaneous Tovaxin in Subjects with CIS, Subcutaneous Daclizumab, NC-100 Novantrone induction, dose ranging GA pilot trial, natalizumab safety and tolerability monitoring; and sub-investigation of Fampridine SR (approved 1/10 brand name Ampyra).

Clinical Trials

• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II) No longer recruiting

Publications

• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW. Lancet Neurol. 2010; 9 (4): 381-90
• Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis Dunn J, Blight A. Current Research Medical Opinion. 2010 submitted
• The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis Dunn, J, Expert Rev. Pharmacoeconomics Outcomes Res.. 2010; 10 (4): 433-440
• CMV Optic Neuritis with Extensive Tracking along the Visual Pathway Pershing S, Dunn J, Khan A, Liao JY, J Neuro-Ophthalmology. 2009; 29 (3): 223-226
• Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK,Campagnolo D, Deutsch F, Arnold D, Multiple Sclerosis. 2008 Apr 18